New Zealand markets close in 1 hour 34 minutes

BIIB Oct 2024 235.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
17.90-1.00 (-5.29%)
As of 02:21PM EDT. Market open.
Full screen
Previous close18.90
Expiry date2024-10-18
Day's range17.90 - 17.90
Contract rangeN/A
Open interest236
  • Investor's Business Daily

    Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails

    Sage Therapeutics said Wednesday its Biogen-partnered treatment for essential tremor failed in a study, leading Sage stock to collapse.


    Sage Therapeutics Stock Slides as Pipeline Thins

    Shares of the biotech Sage Therapeutics plummeted Wednesday morning, after a trial failure knocked away one of the few promising programs in its pipeline. Sage shares started the year at $21.67, and were trading in the $50 range as recently as the spring of 2023. In an announcement made alongside its partner Biogen early Wednesday, Sage said its drug SAGE-324 had failed to ease involuntary shaking in patients with a condition known as essential tremor in a mid-stage trial.

  • Insider Monkey

    Is Biogen (BIIB) an Underappreciated Stock?

    Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” second quarter 2024 investor letter. A copy of the letter can be downloaded here. During the quarter, the strategy returned -1.9% net of fees compared to the S&P 500’s 4.3% return. According to a three-factor performance attribution model, allocation and interaction effects […]